Anti-Human PD-L2-Anti-Human PD-L2代理/參數/廠家-一抗-艾美捷科技有限公司

PRODUCT CENTER

一抗

產品中心

當前位置：首頁 > 產品中心 > 免疫學產品 > 一抗

中文名稱: Anti-Human PD-L2

英文名字: Anti-Human PD-L2

供應商: ReliaTech

產品貨號: 101-M604

產品報價: ￥詢價/100ug

產品說明書: 點擊查看

購買方式: 90%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金，在線支付寶及網銀支付，或直接與我們電話聯系400-6800-868

產品新聞

背景資料: T cells require a signal induced by the engagement of the T cell receptor and a “costimulatory” signal(s) through distinct T cell surface molecules for optimal T cell activation and tolerance. Members of the B7 superfamily of counter-receptors were identified by their ability to interact with costimulatory molecules found on the surface of T cells. Members of the B7 superfamily include B71 (CD80), B72 (CD86), B7H1 (PDL1), B7H2 (B7RP1), B7H3, and PDL2 (B7DC). B7 proteins are immunoglobulin (Ig) superfamily members with extracellular IgV-like and IgC-like domains and short cytoplasmic domains. Among the family members, they share from 20-40% amino acid (aa) sequence identity. The cloned human PDL2 cDNA encodes a 273 aa type I membrane precursor protein with a putative 20 aa signal peptide, a 201 aa extracellular region containing one V-like and one C-like Ig domain, a 24 aa transmembrane region, and a 28 aa cytoplasmic domain. The extracellular domains of mouse and human PDL2 share approximately 70% aa sequence identity. PDL2 is one of two ligands for programmed death1 (PD1), a member of the CD28 family of immunoreceptors. The other identified ligand is PDL1. Human PDL1 and PDL2 share approximately 41% aa sequence identity and have similar functions. PDL2 is broadly expressed in tissues. Highest expression was detected by Northern blot analysis in heart, placenta, liver, pancreas, spleen, and lymph node. Lower amounts of expression were observed in lung, smooth muscle, and thymus. Expression of PDL2 on antigen presenting cell has been examined in detail. Resting B cells, monocytes and dendritic cells do not express PDL2, expression however can be induced by LPS or BCR activation in B cells, INFγ treatment in monocytes, or LPS plus IFN γ treatment of dendritic cells. PD L2 expression is also up regulated in a variety of tumor cell lines. On previously activated T cells, PDL2 interaction with PD1 inhibits TCRmediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. In contrast, a costimulatory function for the PDL2 on resting T cells activated with suboptimal TCR signals has also been reported.

應用類型: WB

免疫原: 該Anti-Human PD-L2的詳細信息查看ReliaTech提供的產品說明書。

來源宿主: 該Anti-Human PD-L2的詳細信息查看ReliaTech提供的產品說明書。

反應性: 該Anti-Human PD-L2的詳細信息查看ReliaTech提供的產品說明書。

保存建議: 該Anti-Human PD-L2的詳細信息查看ReliaTech提供的產品說明書。溶解建議：Centrifuge vial prior to opening. Reconstitute the antibody with 500 μl sterile PBS and the final concentration is 200 μg/ml.

其他: ReliaTech全稱為受體配體技術有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，總部位于德國不倫瑞克，是一家后基因組生物技術公司。ReliaTech主要專注于受體和配體的發現與研究。此外，ReliaTech也開發應用于血管與淋巴管生成研究的相關高品質試劑。目前ReliaTech提供近2800款產品，產品線主要包括重組蛋白(細胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。